Dermapharm Holding SEFRA:DMP 87 Quick Ratio is 1.08 as of Mar. 2026, which is 12% below its 10-year median of 1.23. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 997 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 63.09% on this metric.
Dermapharm Holding SE has a quick ratio of 1.08. It generally indicates good short-term financial strength.
The historical rank and industry rank for Dermapharm Holding SE's Quick Ratio or its related term are showing as below:
FRA:DMP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.41 Med: 1.23 Max: 2.33
Current: 1.08
During the past 13 years, Dermapharm Holding SE's highest Quick Ratio was 2.33. The lowest was 0.41. And the median was 1.23.
FRA:DMP's Quick Ratio is ranked worse than 63.09% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs FRA:DMP: 1.08
Dermapharm Holding SE (FRA:DMP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Dermapharm Holding SE Quick Ratio Related Terms
Dermapharm Holding SE Quick Ratio Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMP vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Dermapharm Holding SE's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (FRA:DMP) has a Quick Ratio of 1.08 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Dermapharm Holding SE and its competitors. This is 12% below median its historical median of 1.23. Over the past decade, Dermapharm Holding SE's Quick Ratio has ranged from 0.41 to 2.33. According to the industry distribution chart, Dermapharm Holding SE ranks #629 out of 997 companies in the Drug Manufacturers industry, placing it in the top 63.1%.
Is Dermapharm Holding SE's Quick Ratio too high?
Dermapharm Holding SE's current Quick Ratio of 1.08 is 12% below median its 10-year median of 1.23. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 2.33. The Drug Manufacturers industry median Quick Ratio is 1.45. Dermapharm Holding SE's value of 1.08 is 25.5% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #629 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #629 out of 997 companies for Quick Ratio. This places Dermapharm Holding SE in the lower half of its industry. The industry median Quick Ratio is 1.45. Dermapharm Holding SE's value of 1.08 is 25.5% below this benchmark. Historically, Dermapharm Holding SE's own Quick Ratio has ranged from 0.41 to 2.33 over the past decade. While the company's 10-year median is 1.23 vs. the industry median of 1.45, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Quick Ratio of 1.08 is 25.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Quick Ratio is 1.08, which is 12% below median its own 10-year median of 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current Quick Ratio is 1.08, which is 12% below median its 10-year median of 1.23 and 25.5% below the Drug Manufacturers industry median of 1.45. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current Quick Ratio is 1.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11.
GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.
Key valuation signals for FRA:DMP:
Quick Ratio: 1.08 (12% below median its 10-year median of 1.23)
GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
Industry Position: 25.5% below the Drug Manufacturers median (#629 of 997)
No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score
Get the complete analysis for FRA:DMP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMP has been successfully added to your 
